01 January 2002
Assessment of iron metabolism in children with chronic hepatitis B - prognostic factor in interferon alpha therapy.
Andrzej Chrobot, Agnieszka Monika Chrobot, Anna Szaflarska-SzczepanikMed Sci Monit 2002; 8(4): CR269-273 :: ID: 420869
Abstract
BACKGROUND: The aim of the study was to assess iron metabolism in childrenwith chronic hepatitis B and to establish whether it had any influence on the results of interferon alphatherapy. MATERIAL/METHODS: The study was carried out in a group of 38 children aged from 2 to 16 yearswith chronic hepatitis B diagnosed according to serological, biochemical and histopathological criteria.All the patients were treated according to the commonly adopted schedule: interferon alpha administeredsubcutaneously three times a week at 3 MIU doses for 20 weeks. During the therapy and one-year follow-upafter its completion, biochemical liver function parameters, serological HBV markers, and iron and ferritinlevels were monitored. RESULTS: The therapy resulted in obtaining seroconversion in the HBe system in9 patients (23.68%). Liver bioptates in that group of patients demonstrated more advanced changes dueto inflammatory activity and fibrosis processes, significantly higher values of alanine aminotransferase,lower serum levels of iron and ferritin with more pronounced difference in ferritin levels, althoughthe differences reached no statistical significance. CONCLUSIONS: No disturbances of iron metabolismwere observed in children with chronic hepatitis B. In the group of patients with detectable seroconversionin the Hbe system resulting from interferon alpha therapy, lower serum levels of iron and ferritin wereobserved. Routine determinations of serum iron and ferritin levels as a prognostic factor for positiveresponse to interferon alpha seem to be of little use, especially in children, in whom no iron accumulationin liver tissue is observed in histopathological assessment of liver bioptates
Keywords: Adolescent, Alanine Transaminase, Antiviral Agents, Child, Child, Preschool, ferritin, Follow-Up Studies, Hepatitis B Antibodies, Hepatitis B e Antigens, Hepatitis B, Chronic, Interferon-alpha, Iron, Liver Cirrhosis
Editorial
01 January 2025 : Editorial
Editorial: The Human Cell Atlas. What Is It and Where Could It Take Us?DOI: 10.12659/MSM.947707
Med Sci Monit 2025; 31:e947707
In Press
Clinical Research
Factors Affecting Medication Adherence in Middle-Aged and Elderly Patients in China: A Cross-Sectional StudyMed Sci Monit In Press; DOI: 10.12659/MSM.945805
Review article
Characteristics and Associated Risk Factors of Broad Ligament Hernia: A Systematic ReviewMed Sci Monit In Press; DOI: 10.12659/MSM.946710
Clinical Research
Cost-Effective Day Surgery for Arteriovenous Fistula Stenosis: A Viable Model for Hemodialysis PatientsMed Sci Monit In Press; DOI: 10.12659/MSM.946128
Clinical Research
Impact of Periodontal Treatment on Early Rheumatoid Arthritis and the Role of Porphyromonas gingivalis Anti...Med Sci Monit In Press; DOI: 10.12659/MSM.947146
Most Viewed Current Articles
17 Jan 2024 : Review article 6,963,777
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
16 May 2023 : Clinical Research 700,314
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
01 Mar 2024 : Editorial 23,719
Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and ...DOI :10.12659/MSM.944204
Med Sci Monit 2024; 30:e944204
28 Jan 2024 : Review article 18,460
A Review of IgA Vasculitis (Henoch-Schönlein Purpura) Past, Present, and FutureDOI :10.12659/MSM.943912
Med Sci Monit 2024; 30:e943912